Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yttrium 90-radiolabelled OTSA 101 - OncoTherapy Science

Next Previous
Drug Profile

Yttrium 90-radiolabelled OTSA 101 - OncoTherapy Science

Alternative Names: Frizzled homologue 10 antibodies - OncoTherapy Science; Frizzled-10 antibodies - OncoTherapy Science; Fz-10 antibodies - OncoTherapy Science; FZD10 monoclonal antibodies - OncoTherapy Science; hFz10 antibodies - OncoTherapy Science; OTSA 101 DTPA-90Y; OTSA101; TT641 pAb - OncoTherapy Science

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoTherapy Science
  • Developer Centre Leon Berard; OncoTherapy Science
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals; Radiosensitisers
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Synovial sarcoma

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Synovial-sarcoma(Second-line therapy or greater) in Japan (IV, Injection)
  • 13 Jul 2023 Discontinued - Phase-I for Synovial sarcoma(Inoperable/unresectable, Second-line therapy or greater) in France (IV), prior to March 2023 (OncoTherapy Science pipeline, July 2023)
  • 31 Mar 2023 Yttrium 90-radiolabelled OTSA 101 is still in phase I trials for Synovial-sarcoma (Refractory metastatic disease, Second-line therapy or greater) in Japan (IV, Injection) (NCT04176016) (OncoTherapy Science pipeline, July 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top